


The claims defining the invention are as follows:


1. A compound having the structure of Formula I:




Formula I

or a pharmaceutically acceptable salt thereof, wherein:

A is selected from the group consisting of A1 and A2, :



A1



A2

X is a (5- to 14-membered)heteroaryl containing 1-3 heteroatoms;

R¹ is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₃-C₈)cycloalkyl, and (C₂-C₆)alkenyl; wherein the (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₃-C₈)cycloalkyl, and (C₂-C₆)alkenyl are optionally substituted with one to three substituents each independently selected from the group consisting of fluoro, hydroxy and (C₁-C₆)alkoxy;

R^{2a} and R^{2b}, at each occurrence, are independently selected from the group consisting of hydrogen, fluoro, cyano, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₈)cycloalkyl, and phenyl; wherein the (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-

C₈)cycloalkyl, and phenyl are optionally substituted with one to three substituents each independently selected from the group consisting of cyano, hydroxy, (C₁-C₃)alkyl, hydroxy(C₁-C₃)alkyl, and fluoro;

R^{4a} and R^{4b} are each independently selected from the group consisting of hydrogen, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, and (C₁-C₆)alkoxy(C₁-C₆)alkyl, wherein the (C₁-C₆)alkyl, (C₁-C₆)alkoxy, or (C₁-C₆)alkoxy(C₁-C₆)alkyl, are optionally substituted with one to three substituents independently selected from the group consisting of cyano, hydroxy, and fluoro;

R^{5a} and R^{5b}, at each occurrence, are independently selected from the group consisting of hydrogen, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, and (C₁-C₆)alkoxy(C₁-C₆)alkyl, wherein the (C₁-C₆)alkyl, (C₁-C₆)alkoxy, or (C₁-C₆)alkoxy(C₁-C₆)alkyl, are optionally substituted with one to three substituents each independently selected from the group consisting of cyano, hydroxy and fluoro;

R⁶ and R⁷ are each independently selected from the group consisting of hydrogen, cyano, halogen, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, and halo(C₁-C₆)alkyl, and -OR⁹; provided that R⁶ and R⁷ cannot both be hydroxy;

R⁹ is selected from the group consisting of hydrogen and (C₁-C₆)alkyl; wherein the (C₁-C₆)alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of cyano, hydroxy and fluoro;

z is an integer selected from 1 or 2;

y is an integer selected from 1, 2, 3 or 4;

 is a bond that is connected to any carbon atom of ring B or ring C that is chemically permissible;

m is an integer selected from 1, 2, 3 or 4;

n is an integer selected from 0 or 1;

W is carbon or oxygen;

ring B is optionally substituted with up to five R¹⁰, wherein each R¹⁰ is independently selected from the group consisting of halogen, cyano, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, (C₁-C₆)alkylthio, -SF₅ and (C₃-C₆)cycloalkyl, wherein the (C₃-C₆)cycloalkyl is optionally substituted with up to three substituents independently selected from the group consisting of halogen, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, and halo(C₁-C₆)alkoxy; or two R¹⁰ substituents taken together with the carbon atom(s) to which they are attached form a geminal (C₃-C₆)cycloalkyl that is

optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, and halo(C₁-C₆)alkoxy;

ring C is optionally substituted with up to four R¹¹ such that substitution occurs at any carbon atom that is chemically permissible, and wherein each R¹¹ is independently selected from the group consisting of halogen, cyano, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, (C₁-C₆)alkylthio, -SF₅, (C₃-C₆)cycloalkyl, and (4- to 6-membered)heterocycloalkyl, wherein the (C₃-C₆)cycloalkyl and (4- to 6-membered)heterocycloalkyl moieties are optionally substituted with up to three halogen, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, or hydroxy(C₁-C₆)alkyl; or two R¹¹ taken together with the carbon atom(s) to which they are attached form a (C₃-C₆)cycloalkyl or a (4- to 6-membered)heterocycloalkyl, wherein the (C₃-C₆)cycloalkyl and (4- to 6-membered)heterocycloalkyl moieties are each optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, and halo(C₁-C₆)alkoxy;

ring D is optionally substituted with up to four R¹², wherein each R¹² is independently selected from the group consisting of halogen, cyano, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, (C₁-C₆)alkylthio, -SF₅, (C₃-C₆)cycloalkyl and (4- to 6-membered)heterocycloalkyl, wherein the (C₃-C₆)cycloalkyl and (4- to 6-membered)heterocycloalkyl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, and halo(C₁-C₆)alkoxy; and


----- is a single or double bond.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is represented by:

- Xi) a (5- to 6-membered)heteroaryl containing 1-2 heteroatoms;
- Xii) a (6-membered)heteroaryl containing 1-2 heteroatoms; or
- Xiii) a (5- membered)heteroaryl containing 1-2 heteroatoms.

3. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein X is a (5-membered)heteroaryl selected from the group consisting of triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, isothiazolyl, thiazolyl, isoxazolyl, and oxazolyl.

4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein X is imidazolyl.
5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein A is selected from A1 as depicted below:



A1

wherein:

R^1 is selected from the group consisting of hydrogen, halogen, cyano, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₃-C₈)cycloalkyl, and (C₂-C₆)alkenyl; wherein the (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₃-C₈)cycloalkyl, and (C₂-C₆)alkenyl are optionally substituted with one to three substituents each independently selected from the group consisting of fluoro, hydroxy and (C₁-C₆)alkoxy;

R^{2a} and R^{2b} , at each occurrence, are independently selected from the group consisting of hydrogen, fluoro, cyano, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₈)cycloalkyl, and phenyl; wherein the (C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₃-C₈)cycloalkyl, and phenyl are optionally substituted with one to three substituents each independently selected from the group consisting of cyano, hydroxyl, (C₁-C₃)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, hydroxy(C₁-C₃)alkyl, and fluoro;

R^{4a} and R^{4b} are each independently selected from the group consisting of hydrogen, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, and (C₁-C₆)alkoxy(C₁-C₆)alkyl, wherein the (C₁-C₆)alkyl, (C₁-C₆)alkoxy, or (C₁-C₆)alkoxy(C₁-C₆)alkyl, are optionally substituted with one to three substituents independently selected from the group consisting of cyano, hydroxy, and fluoro; R^{5a} and R^{5b} , at each occurrence, are independently selected from the group consisting of hydrogen, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, and (C₁-C₆)alkoxy(C₁-C₆)alkyl, wherein the (C₁-C₆)alkyl, (C₁-C₆)alkoxy, or (C₁-C₆)alkoxy(C₁-C₆)alkyl, are optionally substituted with one to three substituents each independently selected from the group consisting of cyano, hydroxy, and fluoro;

R^6 and R^7 are each independently selected from the group consisting of hydrogen, cyano, halogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, and halo(C₁-C₆)alkyl, and -OR⁹; provided that R^6 and R^7 cannot both be hydroxy;

R^9 is selected from the group consisting of hydrogen and (C₁-C₆)alkyl; wherein the (C₁-C₆)alkyl is optionally substituted with one to three substituents each independently selected from the group consisting of cyano, hydroxy, and fluoro;

z is an integer of 1;

y is an integer selected from 1 or 2;

 is a bond that is connected to any carbon atom of ring B or ring C that is chemically permissible;

m is 1;

n is an integer selected from 0 or 1;

W is carbon or oxygen;

ring B is optionally substituted with up to five R^{10} , wherein each R^{10} is independently selected from the group consisting of halogen, cyano, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, (C₁-C₆)alkylthio, -SF₅ and (C₃-C₆)cycloalkyl, wherein the (C₃-C₆)cycloalkyl is optionally substituted with up to three halogen, hydroxyl, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, or hydroxy(C₁-C₆)alkyl; or two R^{10} taken together with the carbon atom(s) to which they are attached form a (C₃-C₆)cycloalkyl that is optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, and halo(C₁-C₆)alkoxy;

ring C is optionally substituted with up to four R^{11} such that substitution occurs at any carbon atom that is chemically permissible, and wherein each R^{11} is independently selected from the group consisting of halogen, cyano, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, (C₁-C₆)alkylthio, -SF₅, (C₃-C₆)cycloalkyl, and (4- to 6-membered)heterocycloalkyl, wherein the (C₃-C₆)cycloalkyl and (4- to 6-membered)heterocycloalkyl moieties are optionally substituted with one to three substituents selected from halogen, hydroxy, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, or hydroxy(C₁-C₆)alkyl; or two R^{11} taken together with the carbon atom(s) to which they are attached form a (C₃-C₆)cycloalkyl or a (4- to 6-membered) heterocycloalkyl, wherein the (C₃-C₆)cycloalkyl and (4- to 6-membered)heterocycloalkyl moieties are each optionally substituted with one to three

substituents independently selected from the group consisting of halogen, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, and halo(C₁-C₆)alkoxy;

ring D is optionally substituted with up to four R¹², wherein each R¹² is independently selected from the group consisting of halogen, cyano, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, (C₁-C₆)alkylthio, -SF₅, (C₃-C₆)cycloalkyl and (4- to 6-membered)heterocycloalkyl, wherein the (C₃-C₆)cycloalkyl and (4- to 6-membered)heterocycloalkyl moieties are optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, (C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkoxy, (C₁-C₆)alkoxy(C₁-C₆)alkyl, halo(C₁-C₆)alkyl, and halo(C₁-C₆)alkoxy; and

----- is a single or double bond.

6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein:

R¹ is (C₁-C₆)alkyl;

R^{2a}, R², R^{4a}, R^{4b}, R^{5a} and R^{5b} are each independently selected from hydrogen or (C₁-C₆)alkyl;

R⁶ and R⁷ are each independently hydrogen;

z and y are each 1;

 is a bond that is connected to any carbon atom of ring B or ring C that is chemically permissible;

m is 1;

n is an integer selected from 0 or 1;

W is carbon or oxygen;

ring B is optionally substituted with up to three R¹⁰, wherein each R¹⁰ is independently selected from halogen or (C₁-C₆)alkyl;

ring C is optionally substituted with up to three R¹¹ such that substitution occurs at any carbon atom that is chemically permissible, and wherein each R¹¹ is independently selected from halogen, (C₁-C₆)alkyl, or halo(C₁-C₆)alkyl; or two R¹¹ taken together with the carbon atom(s) to which they are attached form a (C₃-C₆)cycloalkyl or a (4- to 6-membered) heterocycloalkyl, wherein the (C₃-C₆)cycloalkyl and (4- to 6-membered)heterocycloalkyl moieties are each optionally substituted with one to three substituents independently selected from halogen or (C₁-C₆)alkyl;

ring D is optionally substituted with up to three R^{12} , wherein each R^{12} is independently selected from the group consisting of halogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, -SF₅, and (C₃-C₆)cycloalkyl, wherein the (C₃-C₆)cycloalkyl is optionally substituted with one to three substituents independently selected from halogen, (C₁-C₆)alkyl, or halo(C₁-C₆)alkyl;

and ----- is a single or double bond.

7. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is a (C₁-C₆)alkyl, wherein the (C₁-C₆)alkyl is methyl; and

R^{2a} , R^2 , R^{4a} , R^{4b} , R^{5a} and R^{5b} are each independently

i) hydrogen; or


ii) (C₁-C₆)alkyl, wherein the (C₁-C₆)alkyl is methyl.

8. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl; and R^{2a} , R^2 , R^{4a} , R^{4b} , R^{5a} and R^{5b} are each independently hydrogen.

9. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl; R^{2a} , R^{2b} , R^{5a} and R^{5b} are each independently hydrogen; and one of R^{4a} and R^{4b} is hydrogen and the other is methyl.

10. The compound according to claim 7, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl; one of R^{2a} and R^{2b} is hydrogen and the other is methyl; R^{4a} , R^{4b} , R^{5a} and R^{5b} are each independently hydrogen.

11. The compound according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein m is 1, W is an oxygen atom, n is an integer selected from 0 or 1, and ----- represents a double bond, such that A is represented by a Formula selected from the group consisting of A1a, and A1b,:



wherein:

X is a (5-membered)heteroaryl selected from triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, isothiazolyl, thiazolyl, isoxazolyl, or oxazolyl;

R¹ is (C₁-C₆)alkyl;

R^{2a}, R^{2b}, R^{4a}, R^{4b}, R^{5a} and R^{5b} are each independently selected from hydrogen or (C₁-C₆)alkyl;

R⁶ and R⁷ are each independently hydrogen;

z and y are each 1;


ring B is optionally substituted with up to three R¹⁰, wherein each R¹⁰ is independently selected from halogen or (C₁-C₆)alkyl;

ring C is optionally substituted with up to three R¹¹ such that substitution occurs at any carbon atom that is chemically permissible, and wherein each R¹¹ is independently selected from halogen, (C₁-C₆)alkyl, or halo(C₁-C₆)alkyl; or two R¹¹ taken together with the carbon atom(s) to which they are attached form a (C₃-C₆)cycloalkyl or a (4- to 6-membered) heterocycloalkyl, wherein the (C₃-C₆)cycloalkyl and (4- to 6-membered) heterocycloalkyl moieties are each optionally substituted with one to three substituents independently selected from halogen or (C₁-C₆)alkyl; and

ring D is optionally substituted with up to three R¹², wherein each R¹² is independently selected from the group consisting of halogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, -SF₅, and (C₃-C₆)cycloalkyl, wherein the (C₃-C₆)cycloalkyl is optionally substituted with one to three substituents independently selected from halogen, (C₁-C₆)alkyl, or halo(C₁-C₆)alkyl.

12. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein X is a (5-membered)heteroaryl, wherein the heteroaryl is imidazolyl; and R¹ is a (C₁-C₆)alkyl, wherein the alkyl is methyl.

13. The compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein m is 1, W is an oxygen atom, and n is 1, such that A is represented by Formula A1a:



A1a

wherein:

- X is a (5- membered)heteroaryl, and the (5- membered)heteroaryl is imidazolyl;
- R¹ is (C₁-C₆)alkyl;
- R^{2a}, R^{2b}, R^{4a}, R^{4b}, R^{5a} and R^{5b} are each independently selected from hydrogen or (C₁-C₆)alkyl;
- R⁶ and R⁷ are each independently hydrogen;
- z and y are each 1; and

ring B is optionally substituted with one to two R¹⁰, wherein each R¹⁰ is selected from halogen or (C₁-C₆)alkyl; ring C is optionally substituted with one to two R¹¹, wherein each R¹¹ is selected from (C₁-C₆)alkyl or halo(C₁-C₆)alkyl; or two R¹¹ taken together with the carbon atom(s) to which they are attached form a (C₃-C₆)cycloalkyl or a (4- to 6-membered)heterocycloalkyl; and ring D is optionally substituted with one to three R¹², wherein each R¹² is selected from halogen, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, halo(C₁-C₆)alkyl, halo(C₁-C₆)alkoxy, -SF₅, and (C₃-C₆)cycloalkyl optionally substituted with one or two substituents selected from methyl or trifluoromethyl.

14. The compound according to claim 13, or a pharmaceutically acceptable salt thereof, wherein:

each R¹⁰ is:

- i) halogen selected from fluoro or chloro, or
- ii) (C₁-C₆)alkyl, wherein the (C₁-C₆)alkyl is methyl;

each R¹¹ is:

- i) (C₁-C₆)alkyl, wherein the (C₁-C₆)alkyl is methyl; or
- ii) halo(C₁-C₆)alkyl, wherein the halo(C₁-C₆)alkyl is selected from fluoromethyl, trifluoromethyl, or trifluoroethyl; or

two R¹¹ taken together with the carbon atom(s) to which they are attached form:


- i) a (C₃-C₆)cycloalkyl, wherein the (C₃-C₆)cycloalkyl is cyclobutyl; or

ii) a (4- to 6-membered)heterocycloalkyl wherein the (4- to 6-membered)heterocycloalkyl is an oxetanyl, and

each R^{12} is:

- i) halogen selected from fluoro or chloro;
- ii) (C_1-C_6) alkyl, wherein the (C_1-C_6) alkyl is methyl;
- iii) (C_1-C_6) alkoxy, wherein the (C_1-C_6) alkoxy is methoxy;
- iv) halo (C_1-C_6) alkyl, wherein the halo (C_1-C_6) alkyl is selected from fluoromethyl, trifluoromethyl, or trifluoroethyl;
- v) halo (C_1-C_6) alkoxy, wherein the halo (C_1-C_6) alkoxy is selected from fluoromethoxy, fluoroethoxy, or difluoroethoxy;
- vi) $-SF_5$; or
- vii) (C_3-C_6) cycloalkyl, wherein the (C_3-C_6) cycloalkyl is cyclopropyl optionally substituted with one to two substituents selected from methyl and trifluoromethyl.

15. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein m is 1, W is an oxygen atom, and n is 1, such that A is represented by Formula A1b:



wherein:

- X is a (5- membered)heteroaryl, and the (5- membered)heteroaryl is imidazolyl;
- R^1 is (C_1-C_6) alkyl;
- R^{2a} , R^{2b} , R^{4a} , R^{4b} , R^{5a} and R^{5b} are each independently selected from hydrogen or (C_1-C_6) alkyl;
- R^6 and R^7 are each independently hydrogen;
- z and y are each 1; and
- ring B is optionally substituted with one to two R^{10} , wherein each R^{10} is selected from halogen or (C_1-C_6) alkyl; and ring D is optionally substituted with one to three R^{12} , wherein each R^{12} is selected from halogen, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, halo (C_1-C_6) alkyl,

halo(C₁-C₆)alkoxy, -SF₅, and (C₃-C₆)cycloalkyl optionally substituted with one or two substituents selected from methyl or trifluoromethyl.

16. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

2-(((1*aS*,7*bS*)-2,2-Dimethyl-6-(trifluoromethoxy)-1*a*,2-dihydrocyclopropa[*c*]chromen-7*b*(1*H*)-yl)methyl)-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-(((1*aS*,7*bS*)-2,2-Dimethyl-6-(trifluoromethyl)-1*a*,2-dihydrocyclopropa[*c*]chromen-7*b*(1*H*)-yl)methyl)-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-(((1*aS*,7*bS*)-6-(1,1-difluoroethoxy)-1*a*,2-dihydrocyclopropa[*c*]chromen-7*b*(1*H*)-yl)methyl)-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

2-(((1*aS*,7*bS*)-4-chloro-6-(trifluoromethyl)-1*a*,2-dihydrocyclopropa[*c*]chromen-7*b*(1*H*)-yl)methyl)-7-(4-methyl-1*H*-imidazol-1-yl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione;

7-(4-methyl-1*H*-imidazol-1-yl)-2-(((1*aR*,7*bR*)-6-[1-(trifluoromethyl)cyclopropyl]-1*a*,2-dihydrocyclopropa[*c*]chromen-7*b*(1*H*)-yl)methyl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione; and

7-(4-methyl-1*H*-imidazol-1-yl)-2-(((1*aS*,7*bS*)-6-(trifluoromethoxy)-1*a*,2-dihydrocyclopropa[*c*]chromen-7*b*(1*H*)-yl)methyl)-3,4-dihydro-2*H*-pyrido[1,2-*a*]pyrazine-1,6-dione.

17. The compound according to any one of claims 1-16, or a pharmaceutically acceptable salt thereof, for use in the treatment of neurodegeneration and psychiatric disorders, including Alzheimer's disease or Niemann-Pick disease type C.

18. A pharmaceutical composition comprising a compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.

19. Use of a compound according to any one of claims 1-16 or a pharmaceutical composition according to claim 18, for the manufacture of a medicament for treating Alzheimer's disease or Niemann-Pick disease type C, or for reducing beta-amyloid production.